학술논문

COST-EFFECTIVENESS OF PEMBROLIZUMAB AS AN ADJUVANT TREATMENT FOR ADULTS AND ADOLESCENTS AGED 12 YEARS AND OLDER WITH RESECTED STAGE IIB/ IIC MELANOMA IN FRANCE
Document Type
Journal
Source
VALUE IN HEALTH; DEC 2023, 26 12, pS182-pS182, 1p. Supplement: S
Subject
Language
English
ISSN
15244733